Authors
Latest:
Advancing Injectable Drug Quality: Innovations, Compliance, and Sustainability in the Healthcare IndustryWebinar Date/Time: Tue, Nov 5, 2024 9:00 AM EST
Latest:
The Case for Purpose-Built Pharma LIMSLearn how you can bypass lengthy customizations by deploying a purpose-built LIMS. Pre-configured, pre-validated lab information management systems save time and money, reduce risk, keep you focused, and future-proof your lab.
Latest:
Containing Cytotoxic Product during TransportThe purpose of this document is to serve as a case study where a containment device was designed to facilitate “interim containment”, or containment during the portion of a process where the product isn’t inside the enclosure.
Latest:
Size Doesn’t Matter … Under PressureSimplify the scaling of different dosages. Develop on lower dosage tablets to save money. Decrease the need to have multiple tooling sizes in R&D.
Latest:
Annex 1 Considerations for Fill/FinishEquipment and systems for aseptic transfer and manufacture meet cGMP and Annex 1 requirements for pharmaceutical fill and finish.
Latest:
How Excipient Type Influences Self-Emulsifying Drug DeliveryHigh-throughput platforms can be used to develop tertiary phase diagrams, which can be leveraged to identify the most stable SEDDS formulations and excipients for lipid-based drug delivery systems.
Latest:
Through Container Verification of Pharmaceutical Raw Materials with the New Agilent Vaya Handheld Raman SystemThis webcast will describe raw material verification testing through transparent and non-transparent packaging using the new Agilent Vaya handheld Raman system. True through-barrier analysis removes the need for sampling, increasing testing throughput without increasing costs-from clear glass vials to multilayer paper sacks. Live: Europe Broadcast: Thursday, May 14, 2020 at 9am EDT | 2pm BST | 3pm CEST US Broadcast: Thursday, May 14, 2020 at 2pm EDT | 1pm CDT | 11am PDT Asia Pacific Broadcast: Friday, May 15, 2020 at 8:30am IST | 11am CST | 12pm JST | 1pm AEST On demand available after airing until May 14, 2021.
Latest:
The Road to Real-Time Release: At-line NIR TestingAt-line NIR measurements can replace a laboratory HPLC measurement for API content in oral solid-dosage drug manufacturing.
Latest:
Advancements in Encapsulation TechnologyTechnological advancements can address the formulation and dissolution challenges of HPMC polymers.
Latest:
Perspectives on Quality Attributes of Drug Products Containing NanomaterialsIn this article, the contents of a stimulus article produced by the joint subcommittee of the USP Expert Committees on Dosage Forms, Physical Analysis, and Excipients and relevant comments from a workshop session are summarized.
Latest:
Perspectives on Quality Attributes of Drug Products Containing NanomaterialsIn this article, the contents of a stimulus article produced by the joint subcommittee of the USP Expert Committees on Dosage Forms, Physical Analysis, and Excipients and relevant comments from a workshop session are summarized.
Latest:
Perspectives on Quality Attributes of Drug Products Containing NanomaterialsIn this article, the contents of a stimulus article produced by the joint subcommittee of the USP Expert Committees on Dosage Forms, Physical Analysis, and Excipients and relevant comments from a workshop session are summarized.
Latest:
Perspectives on Quality Attributes of Drug Products Containing NanomaterialsIn this article, the contents of a stimulus article produced by the joint subcommittee of the USP Expert Committees on Dosage Forms, Physical Analysis, and Excipients and relevant comments from a workshop session are summarized.
Latest:
Perspectives on Quality Attributes of Drug Products Containing NanomaterialsIn this article, the contents of a stimulus article produced by the joint subcommittee of the USP Expert Committees on Dosage Forms, Physical Analysis, and Excipients and relevant comments from a workshop session are summarized.
Latest:
Perspectives on Quality Attributes of Drug Products Containing NanomaterialsIn this article, the contents of a stimulus article produced by the joint subcommittee of the USP Expert Committees on Dosage Forms, Physical Analysis, and Excipients and relevant comments from a workshop session are summarized.
Latest:
Perspectives on Quality Attributes of Drug Products Containing NanomaterialsIn this article, the contents of a stimulus article produced by the joint subcommittee of the USP Expert Committees on Dosage Forms, Physical Analysis, and Excipients and relevant comments from a workshop session are summarized.
Latest:
Perspectives on Quality Attributes of Drug Products Containing NanomaterialsIn this article, the contents of a stimulus article produced by the joint subcommittee of the USP Expert Committees on Dosage Forms, Physical Analysis, and Excipients and relevant comments from a workshop session are summarized.
Latest:
Perspectives on Quality Attributes of Drug Products Containing NanomaterialsIn this article, the contents of a stimulus article produced by the joint subcommittee of the USP Expert Committees on Dosage Forms, Physical Analysis, and Excipients and relevant comments from a workshop session are summarized.
Latest:
Perspectives on Quality Attributes of Drug Products Containing NanomaterialsIn this article, the contents of a stimulus article produced by the joint subcommittee of the USP Expert Committees on Dosage Forms, Physical Analysis, and Excipients and relevant comments from a workshop session are summarized.
Latest:
Perspectives on Quality Attributes of Drug Products Containing NanomaterialsIn this article, the contents of a stimulus article produced by the joint subcommittee of the USP Expert Committees on Dosage Forms, Physical Analysis, and Excipients and relevant comments from a workshop session are summarized.
Latest:
Perspectives on Quality Attributes of Drug Products Containing NanomaterialsIn this article, the contents of a stimulus article produced by the joint subcommittee of the USP Expert Committees on Dosage Forms, Physical Analysis, and Excipients and relevant comments from a workshop session are summarized.
Latest:
Quality by Design: A CMO's Perspective on Gaining Knowledge Faster and BetterTraditional project decision-making is compared with a QbD approach.
Latest:
Biologics Facilities Expand and Establish New Locations in 2021The latest news about biologics facilities includes various expansions, new locations, and acquisitions in the bio/pharmaceutical space.
Latest:
Detecting Residual Moisture in Lyophilized ProductThere are several common methods for detecting residual moisture in drug products that have been lyophilized; here are some key points to consider when selecting a method or developing one.
Latest:
Mitigating the Risk from Excipient VariabilityThis article reviews sources of excipient variability, including raw materials and processing, both of which may vary from supplier to supplier and from plant to plant for a single manufacturer.
Latest:
Additives and Processing Aids in Pharmaceutical ExcipientsThis article seeks to encourage continued dialogue among stakeholders to achieve consensus regarding excipient additives and processing aids.
Latest:
Understanding Concomitant Components in Pharmaceutical ExcipientsViewpoint: Continued dialogue among pharma stakeholders is needed to achieve consensus regarding excipient composition.
Latest:
Additives and Processing Aids in Pharmaceutical ExcipientsThis article seeks to encourage continued dialogue among stakeholders to achieve consensus regarding excipient additives and processing aids.
Latest:
Polymer Influence on the Rheological Properties of Co-Processed Microcrystalline Cellulose and Sodium CarboxymethylcelluloseIn this study, researchers evaluated the colloidal microcrystalline cellulose (cMCC) suspending agent—a co-processed material of microcrystalline cellulose and sodium carboxymethyl cellulose (NaCMC)—by using a representative pharmaceutical-grade commercial version of cMCC.
Latest:
Accelerating Biosimilar AnalysisMass spectrometry should be utilized effectively to optimize biosimilar analysis, which can reduce development time and cost.
